presentation done by oliver blin

BioGenesisTheEuro-IndiaHealthCluster

ProfOlivierBLINMD,PhD,MBA

PastmemberBoardoftheFrenchMinisterofHealthCo-founderofCompetitivenessclusters

Welcome to the World of Bioclusters


Cluster:::• Thecombinaisoninadefinedgeographicarea• Ofentreprises(industries&SMEs),trainingandresearchentities(publicorprivate)

• Engagedinasynergyofinnovativecommonprojects• Targetingamarketrelatedtoatechnologyandscientificdomain

• Withanimationandnetworking• Astronggovernance


Functionalentity:theProject:::• ThemaintargetofCompetitivenessClusteristoinitiate,help

forthepreparation,validateandfindafinancingforR&Dprojects

• Maincriteria– ProjectsassociatingpublicandprivateR&D– Projectmanagedbyacompanybasedintheregion– Evaluationmadebyexternalexpertstoassesseconomicalandscientificpotential

BioGenesisTheEuro-IndiaHealthCluster Objectives:::

• Aimsareto:– Developemployementandeconomy– Reachacriticalvolume– Increasevisibilityandinternationallisibility– Improveattractivenessoftheterritory

• Butalso…– todevelopinternationalpartnership– Toattractinternationalinvestors– Topotentiateexportcapabilitiesofmembers


5villes2régions

Immunology&therapeuticapplications

Eldely,neurologicaldiseasesandhandicap:ResearchandCare

Infectious,Tropical&EmergingDiseases

RareandOrphanDiseases

MedicalDevices,bio-markersanddiagnosis

Axes

Zones

Training39000students1500PhD

INDUSTRIES>200companies10000directjobs3000jobsR&D

RESEARCH220labs,6000rechearchersLabelsGénopole,CanceropoleInfectiopole,DIRC…

Prod’Innov SantéB O R D E A U XAliments et santé

Medicen

Alsace Biovalley

EuroBioMed


Mainindustrialpartners:::NîmesMontpellier Marseille Nice ToulonMarcoule/Vergèze LaCiotat Sophia-Antipolis LaSeynesurMer


Universities&Researchorganisms:::

BioGenesisTheEuro-IndiaHealthCluster Sponsors:::


• 322projectshavebeenassessed,263ofthemhavebeenapproved

18

3756 59

91

8

6

17 11

19

0

20

40

60

80

100

120

2006 2007 2008 2009 2010

Non approvedApproved

Projectsevaluated&approved:::

July 2010


Projectsapproved&financed:::

• 74projectshavebeenfinancedintheframeofEurobiomedin4years

3

0 0

45

2

0 0

3

11

1 1

5

12

2 22

16

0

2

4

6

8

10

12

14

16

2006 2007 2008 2009 2010

FUIANROseoFP7IMI & ISIARCUS

Nb

of p

roje

cts


Breakdownofthese74projectsbyaxis:::

Others:7

Neurovieillt.:25

Immuno.Cancer:13 DM&Diag.18

Rare&Orphan21

Inf.&tropical:19


EFPIA Company Principle Investigator Institution Principle Investigator

AstraZeneca Hans-GoranHardemark

UniversityofMarseille OlivierBlin

Boehringer-Ingelheim BerndSommer IDIBAPS DavidBartres-Faz

Novartis GeorgesImbert UniversityofLille RégisBordet

Servier esther.schenker UniversityofLeipzig PeterSchonknecht

UCB YvesLamberty UniversityofMurcia Maria-TrinidadHerreroSpitzer

MerckSerono DirkBeher UniversityofEssen PhilippSpitzer

Lilly MichaelJO'neill CNRS FabienneAujard

Janssen JohnAtack INSERM PierrePayoux

Roche SusanneOstrowitzki UniversityofVerona MarinaBentivoglio

Lundbeck JanEgebjerg IRCCS-FBF GiovanniFrisoni

GSK ElaineIrving UNIFG ClaudioBabiloni

MarioNegriInstitute GianluigiForloni

AlzProtect PhilippeVerwaerde

Qualissima SeverinePitel

ExonHit PascaleBeurdeley

InnovativeHealthDiagnostics

XavierRegnaut

AlzhiimerEurope JeanGeorges InnovativeConceptsin

DrugDesignNathalieCompagnone

Advancing science and treatment of Alzheimer’s Disease

ContributionEFPIA:10.6M€

ContributionIMIJU:9.6M€

Matrix development strategy

Cellu

lar

Therapeutic

Challenge

Phase II

Phase Ia/Ib

GO

/NO

GO

Biology

ElectrophysiologyPsychophysiology

ImagingAn

imal

HV Selec

ted

Patie

nt

xy

z

TotalBudget:30M€


International:::

• InternationalR&Dprojects• Internationalcollectiveactions• Meetings• Partnerships• Presence

1 VirbacSA

2 InstitutdeRecherchepourleDéveloppement– UMR177

3 InstitutodeSaludCarlosIII

5IndianCouncilofMedicalResearch– Instituteofpathology

6 UniversidadPeruanaCayetanoHeredia

7 InstitutPasteurdeTunis

8 ConsultingGroup

9 Inprogress

FP7sept.2007

3,97M€totalbudget2,74M€grants

Amastigotes

(Lemesre Jean-Loup,IRD)

LeishmaniosisVaccine


• EurobiomedorganisedamissionwithotherHealthClustersduringBio-Bangalorein2008:– New-Delhi 21/04/08– Hyderabad 22/04/08– Bangalore 23&24/04/08

• 5clustersparticipated:– Medicen(Ile-de-France)– LyonBiopôle(RhôneAlpes)– AlsaceBiovalley(Alsace)– AtlanticBiotherapies(PaysdeLoire)– Eurobiomed(LR– PACA):ADME,Qualissima,…

Bio-Bangalore2008:::

BioGenesisTheEuro-IndiaHealthCluster Internationalpresence:::

Eurobiomedrepresentatives

• OnerepresentantinSanDiego

• OlivierBlinisrepresentingEurobiomedandotherHealthClustersinIndia

Shanghai

Milan

BruxellesLondres

Hyderabad

SanDiegoNewYork

Eurobiomed partners


Internationalpartnerships:::

BioGenesisTheEuro-IndiaHealthCluster HyderabadLocation:::


HyderabadBioIndustry:::

• Hyderabad is the financial, economic and political capital of the state ofAndhra Pradesh. Hyderabad has a population of over 4 million.

• Hyderabad is a major centre for pharmaceuticals: Dr. Reddy's Laboratories,Matrix Laboratories, Hetero Drugs Limited, Divis Labs, Aurobindo PharmaLimited, Lee Pharma and Vimta Labs.

• Initiatives such as Genome Valley, Fab City and the Nano Technology parkare expected to create extensive infrastructure in bio-technology.

• Hyderabad is home to numerous research institutes, including the IndianInstitute of Chemical Technology (IICT), Centre for Cellular and MolecularBiology (CCMB), Centre for DNA Fingerprinting and Diagnosis, NationalInstitute of Nutrition (NIN) and International Crops Research Institute forSemi-Arid Crops (ICRISAT).

• Hyderabad has number of renowned universities namely HyderabadCentral University, Osmania University, JNTU, etc.

• Hyderabad is home to many superlative hospitals. Some of the leadinghospitals include Apollo Hospitals, Care Hospitals, Global Hospitals, NIMS,etc.

BioGenesisTheEuro-IndiaHealthCluster BioGenesis :::

BioGenesis is a Non Profit Organization set up to integrate theHealthcare Community in the City of Hyderabad and other cities in Indiaand link it to the World Bioclusters, for mutually beneficial associations.

We also aim:

• To integrate and develop synergies between firms, laboratories, andtraining facilities setting up a network between interested organizationsand develop partnership projects.

• To develop new innovations in the health service.,• To enhance the visibility within the national health sector as well as

international health and life sciences industry.• To accompany the development of business and increase employment

opportunities nationally.


KnowledgeTransferFunding

OutsourcingManpowerResources

OtherRegionalcluster OtherRegionalcluster

MMSEcluster OtherRegionalcluster



• A12yearoldcompany• ManufacturingfacilitiesinHyderabad,India• DeniscosuppliescuttingedgeproductsinorganicsynthesistoPharmaceutical,AgriculturalandSpecialtyChemicalindustries

• Businesssplit:80%Europe/US/Japan,20%India• Historicalfacility(1/2acre)• Newfacility(17acres):20MTs/month,Q2,2011


25

§Created in 2004

§50 employees

§High profile team members with experienced managers

§Offices in Montpellier, Paris, Shanghai, Sao Paulo, Milan, Singapore & Budapest

§ Develops and markets Software Solutions to Visualise and Analyse Medical Images

from all modalities (CT-Scan, MRI, PET, CR/DR, Ultrasound …)

§Myrian Product offering includes Generic Applications and unique Expert Clinical Modules

§Liver Module considered as the best in class on a worldwide basis

§400 installations in 26 countries

§Sales to Hospitals and Clinics, Medical Imaging Centers, Modality, Pacs & Ris vendors

§Partnership with Toshiba for MRI workstations

INTRASENSEaMedicalImagingSoftwareEditor


AsiaticMediquiptsSuratHemal Joshi

YogaPuneMaheshPathak

Sree BhagavathyAgenciesKeralaMr.Subramoniam

AccessDevicesBangaloreDVAshok/Ramesh Shetty

SilverlineSpecialitiesHyderabadGSKChakravarhy

Sree BhagavathyAgenciesChennaiMr.N.T.Srinivasan

ModiMedicareHeadOfficesMumbaiJigish Modi

KrishnaMicromedNewDelhiAlok Sinha

IntrasenseoperatesinIndiathrough3mainchannels:

•OneDistributordedicatedtohigh-endmodules,ModimedicareestablishedinMumbaiandcoveringIndiathrough7sub-distributors.Majorhospitals(Apollo,InstituteofLiver&BiliarySciences,MedantaHospitals,AsianInstituteofGastroenterology,AIMS….)andMedicalImagingCenters(Piramid,Jupiter,AstreImaging….)havebeenalreadyapproached

•Onedistributor,Komega,dedicatedtogenericapplicationandComputer/DigitalRadiologycoveringTiers3hospitals(50to200beds).

•OEMPartneshipswithPACSandRIScompanies.2agreementshavebeenalreadysignedwithMoksha(aPacssupplierfromBangalore)andCentury21,(aPacs/RissupplierfromMumbai).

•Drasticincreaseinthenumberofprivateimagingcenters(CT,MRI,PET/CT)•Remotehospitalsinateleradiologymode.•Transplantsurgeryisnowdevelopinginmorethan15hospitalsacrossthecountry(liver,lungandkidney)

26


Synchron(India)andADME(France)• SYNCHRON:

– 12yearsexperience:oneofthefirstCROsinIndia– 134bedsinAhmedabad– Accesstoalargedatabaseofvolunteers(over7500)– Accesstospecialpopulations:Post-menopausalwomen/Cancerpatients/

Diabeticpatients(clampstudies)/Renalimpairedpatients• EurofinsADMEBIOANALYSES:

– 20yearsexperienceinpharmacokinetics– 7LC-MS/MSinFrance– RegularlyinspectedbyAFSSAPS(everytwoyears)andsuccesfullyinspectedby

FDAinJuly2009• Commonobjective:

– ConductphaseItoIVclinicaltrials,includingbioequivalencestudieswithclinicaltrialinIndiaandbioanalysisinFrance

– FirstprojectstartedinSeptember


28

At the crossroad of 3 major trends

G row ing importance of patient’s role

G row ing role of health authorities

Process internationalisation

Vision:•To be a centre of excellence in pharmaceutical research, training and healthcare provider underpinned by intellectual ability, •A strong worth ethic and a customer centric approach•A “showroom” for Indo-French-European collaborations in science and health (research, care, green architecture)Mission:

•To create a Translational Research Institute within the next 3 years•To allow pharmaceutical companies and drug molecule to be taken from the ‘bench’ to the ‘bedside’ in a cost-effective and timely manner•To provide the highest international standard care


Translational Medecine

Platfom

E-training

Patient Web site

Web platform

Consulting Soft landing gateway25 acres land Genome Valley

Human ResearchPlatformBiology

Clinical Trials

SMOPartners:-Care-Global-NIMS-Indo-Am CH-MNJ CH

Partners:Univ HydCCMBIICTCDFDInstitute of Genetics

CRO

Research ProgramsNew Indigo

BioGenesisIndo-European LifeSciences Competitiveness Cluster


AlzBioIndigoAEuropefundedproject(2010-2012)with:

India:NIMS(Hyderabad)France:Pharmacology(Marseille)Germany:MolecularBiology(Essen)Portugal:Pharmacology(Lisboa)

TotalCSFTau,Phospho-TauandAmyloidbeta(Aβ)inthepatientpopulationasapartoftheNew-Indigoproject

Implementationofcommonmetholodology,neuropsychology,imagingandethicsstandardsinEuropeandIndia


3tracks:•MediAsia•HealthAsia•AgriAsia

ConferenceofEAbadie,PresidentCHMP(EMA)

LaunchoftheAlzBioIndigoproject

TheFuture:MedicalDevicesECRIN FP7 program, WP5 Medical Devices

European Archipelago of Medical Device Marseille Provence

Collaborative project dedicated to medical device and health technologies’

innovation and development

Mutualized TechnologyPlatforms

Network of experts

Services fromconception to

marketing

Virtual simulation « Homme virtuel »

Imaging

Elderly Home Care

Fromconcept….topatientMedicalDevicesIndo-European

OneStopShop


Becomepartofaglobalhealthvillage…

aninnovative andexpandingHealthCluster..


Contact:ProfOlivierBLIN

TelEurope:+33624306802TelIndia:+919951041000

E:[email protected]:http://www.biogenesis.in

E:[email protected]:http://www.eurobiomed.org


Backup


Immunology and therapeutic applications

Treatment and care of ageing, neurological diseases and handicap

Infectious, tropical and emerging pathologies

Rare and orphan diseases

Medical devices, biomarkers and diagnostic

Axis

5 villes 2 régions

Zonage

EDUCATION39 000 students

1 500 doctorates

INDUSTRY> 200 companies

10 000 directs jobs 3 000 in R&D

5 cities 2 Regional Councils

PUBLIC RESEARCHPublic laboratories, > 6 000 researchers,

Génopole Labels Canceropole, Infectiopole…

CompetitivenessclusterEurobiomed


Someprojectsfinancedbythe "Fonds UniqueInterministériel"

• 2.7M€totalbudget

• 1.4M€financing

"InnovativeantiMalariatherapiesand

Diagnostic"

InnoMad

• 5.8M€totalbudget


"DiagnosisandTreatmentofAlzheimer

disease"

DiaTrAl

• 14M€totalbudget


"Newapproachofscreening"

Cell2Lead

The targetis to develop this field.

There is also a big potential in the pharma business.